SiBone (NASDAQ:SIBN - Get Free Report) insider Anshul Maheshwari sold 1,715 shares of the firm's stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $23.19, for a total value of $39,770.85. Following the sale, the insider directly owned 204,870 shares of the company's stock, valued at $4,750,935.30. This represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Anshul Maheshwari also recently made the following trade(s):
- On Monday, November 16th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The stock was sold at an average price of $23.32, for a total value of $108,787.80.
- On Wednesday, November 4th, Anshul Maheshwari sold 3,247 shares of SiBone stock. The stock was sold at an average price of $25.00, for a total value of $81,175.00.
- On Thursday, October 29th, Anshul Maheshwari sold 3,738 shares of SiBone stock. The stock was sold at an average price of $22.50, for a total value of $84,105.00.
- On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The shares were sold at an average price of $19.50, for a total value of $33,754.50.
- On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The shares were sold at an average price of $18.18, for a total value of $60,321.24.
- On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The stock was sold at an average price of $20.11, for a total transaction of $233,999.96.
- On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total transaction of $224,784.56.
SiBone Price Performance
SIBN traded up $0.38 during midday trading on Wednesday, hitting $23.54. The company had a trading volume of 1,120,107 shares, compared to its average volume of 644,914. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.15 and a current ratio of 7.58. The company has a market capitalization of $1.06 billion, a PE ratio of -75.93 and a beta of 0.64. SiBone has a twelve month low of $11.48 and a twelve month high of $25.92. The firm's 50-day simple moving average is $20.56 and its 200-day simple moving average is $16.85.
SiBone (NASDAQ:SIBN - Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. The company had revenue of $55.70 million for the quarter, compared to analyst estimates of $55.31 million. Equities research analysts predict that SiBone will post -0.34 EPS for the current fiscal year.
Institutional Investors Weigh In On SiBone
Several institutional investors have recently modified their holdings of the business. First Light Asset Management LLC raised its stake in shares of SiBone by 51.8% during the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company's stock worth $132,649,000 after buying an additional 2,774,795 shares during the last quarter. Granahan Investment Management LLC lifted its holdings in SiBone by 97.6% in the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company's stock valued at $21,965,000 after buying an additional 858,942 shares during the period. Paradigm Capital Management Inc. NY boosted its stake in SiBone by 113.3% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company's stock valued at $14,228,000 after acquiring an additional 598,300 shares during the last quarter. Renaissance Technologies LLC boosted its stake in SiBone by 101.6% in the first quarter. Renaissance Technologies LLC now owns 472,619 shares of the company's stock valued at $5,969,000 after acquiring an additional 238,219 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in SiBone by 41.8% in the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company's stock valued at $7,816,000 after acquiring an additional 182,465 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on the company. UBS Group upped their price objective on SiBone from $25.00 to $26.00 and gave the stock a "buy" rating in a report on Tuesday, November 3rd. Citigroup reissued a "market outperform" rating on shares of SiBone in a research note on Tuesday, November 3rd. Wall Street Zen upgraded SiBone from a "hold" rating to a "buy" rating in a research report on Saturday, November 7th. TD Cowen boosted their target price on SiBone from $20.00 to $23.00 and gave the stock a "buy" rating in a research report on Tuesday, November 3rd. Finally, Needham & Company LLC cut their price target on SiBone from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Tuesday, November 3rd. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $25.00.
Get Our Latest Stock Analysis on SIBN
About SiBone
(
Get Free Report)
SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider SiBone, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list.
While SiBone currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.